Oseffyl (Teriparatide)

Teriparatide, the active ingredient in Oseffyl, is a peptide hormone presented as a sterile solution for subcutaneous injection use. It is indicated for the treatment of osteoporosis in postmenopausal women and men who are at high risk of fracture.

GNH USA supplies Oseffyl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Clients benefit from reliable logistics, temperature‑controlled shipping where required, and responsive technical support throughout the procurement process.

Teriparatide is used in the management of osteoporosis, a disease characterized by reduced bone mass and increased fracture risk.

Postmenopausal osteoporosis: increases bone mineral density and reduces vertebral and non‑vertebral fracture incidence. Male osteoporosis: stimulates bone formation to improve skeletal strength. Glucocorticoid‑induced osteoporosis: counteracts bone loss associated with long‑term steroid therapy.

Teriparatide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Dizziness - Injection site reactions (pain, redness, swelling) - Hypercalcemia

Serious or Rare Side Effects: - Osteosarcoma (very rare, observed in animal studies) - Severe hypercalcemia - Anaphylactic or severe allergic reactions

Before prescribing Oseffyl, clinicians should consider several safety measures.

Assess calcium levels: correct hypocalcemia before initiating therapy. Monitor bone turnover markers: evaluate treatment response periodically. Avoid in patients with prior radiation therapy to bone: increased risk of osteosarcoma. Use caution in hyperparathyroidism: may exacerbate hypercalcemia. Pregnancy and lactation: contraindicated unless benefits outweigh risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Teriparatide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concurrent bisphosphonates: may blunt anabolic effect of teriparatide. - High-dose calcium or vitamin D supplements: increase risk of hypercalcemia. - Calcitonin therapy: additive calcium‑lowering effect.

Moderate Interactions (Monitor Closely): - Loop diuretics: may increase urinary calcium loss, affecting calcium balance. - Glucocorticoids: may reduce teriparatide efficacy on bone formation. - Thiazide diuretics: may raise serum calcium, requiring monitoring.